Singapore markets closed

iX Biopharma Ltd. (42C.SI)

SES - SES Delayed Price. Currency in SGD
Add to watchlist
0.22000.0000 (0.00%)
At close: 4:58PM SGT

iX Biopharma Ltd.

No. 14-01 Great World City East Tower
1 Kim Seng Promenade
Singapore 237994
65 6235 2270

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Yip Hang LeeExec. Chairman & CEON/AN/A1954
Mr. Sien Lup ChewChief Financial OfficerN/AN/A1963
Dr. Janakan KrishnarajahCOO & Chief Medical OfficerN/AN/AN/A
Dr. Iain Bruce CookChief ScientistN/AN/A1960
Mr. Wei Hsiung Lee ACISJoint Company Sec.N/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SGD.


iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Australia and Singapore. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for major depressive disorder. The company also develops BnoX, a sublingual buprenorphine wafer for the management of acute and chronic moderate to severe pain; Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction; Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, tremor, and chronic inflammation. In addition, it offers LumeniX for skin lightening; and WafeRest for the promotion of sleep. Further, the company promotes and markets nutritional and supplements products through pharmacies, as well as through online; develops and commercializes of nutraceutical products; provides laboratory services; and JD and Tmall e-commerce platforms in China. iX Biopharma Ltd. was founded in 2008 and is headquartered in Singapore.

Corporate governance

iX Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.